Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 8:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Combination of blocks Clear all
Recruiting Phase 2 Interventional Accepts healthy volunteers

PrEPsmart 2-1-1 Pilot

NCT06631365
View directory record Official record
Conditions
HIV-1-infection
Interventions
PrEPsmart mobile app, Truvada
Device · Drug
Lead sponsor
Public Health Foundation Enterprises, Inc.
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 7, 2024 · Synced Sep 15, 2026, 8:45 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Combination Facial Aesthetic Treatment in Millennials

NCT04755595
View directory record Official record
Conditions
Dermatological Non-Disease
Interventions
Botox Cosmetic Injectable Product, Juvéderm Voluma XC, Juvéderm Volbella XC
Drug · Device
Lead sponsor
State University of New York - Downstate Medical Center
Other
Eligibility
24 Years to 40 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Sep 15, 2026, 8:45 PM EDT
Terminated Phase 4 Interventional Results available

Continuous Nerve Block Block vs Combination of Single Block Plus Intravenous Lidocaine for Postoperative Pain.

NCT04208516
View directory record Official record
Conditions
Postoperative Pain
Interventions
Continuous Erector Spinae Plane Nerve Block, Continuous Quadratus Lumborum Nerve Block, Single Erector Spinae Plane Nerve Block, Single Quadratus Lumborum Nerve Block, Lidocaine IV, Ropivacaine 0.5% Injectable Solution, Dexamethasone, Dexmedetomidine, Lidocaine
Procedure · Drug
Lead sponsor
Jeremy Kearns
Other
Eligibility
18 Years to 90 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 15, 2026, 8:45 PM EDT
Completed Phase 1 Interventional

Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance

NCT01197170
View directory record Official record
Conditions
Solid Tumors, Advanced Cancer
Interventions
Anastrozole, Bevacizumab, Everolimus, Sorafenib, Erlotinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Sep 15, 2026, 8:45 PM EDT
Completed Phase 1 Interventional

CD40-L Blockade for Prevention of Acute Graft-Versus-Host Disease

NCT03605927
View directory record Official record
Conditions
Graft-versus-host-disease, GVHD, GVHD, Acute
Interventions
BMS-986004, Sirolimus, Tacrolimus
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
3
States / cities
Duarte, California • Tampa, Florida • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 15, 2026, 8:45 PM EDT
Active, not recruiting No phase listed Observational

A Prospective Study Comparing VivAer to Alternative Surgical Procedures to Treat Nasal Airway Obstruction in Patients With Nasal Valve Dysfunction.

NCT06922955
View directory record Official record
Conditions
Nasal Airway Obstruction
Interventions
Not listed
Lead sponsor
Aerin Medical
Industry
Eligibility
22 Years to 85 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
35
States / cities
Alexander City, Alabama • Birmingham, Alabama • Huntsville, Alabama + 27 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 15, 2026, 8:45 PM EDT
Completed Phase 4 Interventional

A Study In Pediatric Subjects With Asthma Using ADVAIR HFA, ADVAIR HFA With Spacer, And ADVAIR DISKUS

NCT00400608
View directory record Official record
Conditions
Asthma
Interventions
ADVAIR HFA, ADVAIR DISKUS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
4 Years to 11 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
3
States / cities
Huntington Beach, California • Long Beach, California • Medford, Oregon
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 15, 2026, 8:45 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Axelopran and Nivolumab in PD-1-Refractory Metastatic Melanoma

NCT07631325
View directory record Official record
Conditions
Unresectable Cutaneous Melanoma
Interventions
Axelopran, Nivolumab
Drug
Lead sponsor
John Kirkwood
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 15, 2026, 8:45 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)

NCT03203473
View directory record Official record
Conditions
Renal Cancer
Interventions
Ipilimumab, Nivolumab
Drug
Lead sponsor
Toni Choueiri, MD
Other
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
8
States / cities
La Jolla, California • Chicago, Illinois • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 15, 2026, 8:45 PM EDT
Completed Phase 1 Interventional

PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

NCT04887194
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
Sitravatinib, Warfarin, Dextromethorphan, Midazolam, Digoxin, Rosuvastatin, Nivolumab
Drug
Lead sponsor
Mirati Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
5
States / cities
Goshen, Indiana • Austin, Texas • San Antonio, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Sep 15, 2026, 8:45 PM EDT
Active, not recruiting Phase 1 Interventional

D2C7-IT With Atezolizumab for Recurrent Gliomas

NCT04160494
View directory record Official record
Conditions
Malignant Glioma
Interventions
D2C7-IT (6920 ng/mL via convection-enhanced delivery), Atezolizumab (1200 mg every three weeks), D2C7-IT (4613.2 ng/mL via convection-enhanced delivery)
Drug
Lead sponsor
Darell Bigner
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 15, 2026, 8:45 PM EDT
Recruiting Phase 1Phase 2 Interventional

Valproate for the Treatment of Residual Amblyopia

NCT07226141
View directory record Official record
Conditions
Amblyopia, Amblyopia Unilateral, Amblyopia, Anisometropic, Amblyopia Strabismic
Interventions
Valproate, Placebo, Patch
Drug · Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 15, 2026, 8:45 PM EDT
Completed Phase 4 Interventional Results available

Widefield Angiography Guided Targeted-retinal Photocoagulation Combined With Anti VEgf Intravitreal Injections for the Treatment of Ischemic Central Retinal Vein Occlusion, Hemi Retinal Vein Occlusion, and Branch Retinal Vein Occlusion

NCT01710839
View directory record Official record
Conditions
Central Retinal, Hemi Retinal & Brach Retinal Vein Occlusions
Interventions
0.5mg Ranibizumab, Targeted Pan Retinal Photocoagulation
Drug · Procedure
Lead sponsor
Charles C Wykoff, PhD, MD
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
3
States / cities
Houston, Texas • Katy, Texas • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Sep 7, 2017 · Synced Sep 15, 2026, 8:45 PM EDT
Active, not recruiting Phase 1 Interventional

SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab

NCT03161431
View directory record Official record
Conditions
Melanoma Stage III, Melanoma Stage IV
Interventions
SX-682, Pembrolizumab
Drug · Biological
Lead sponsor
Syntrix Biosystems, Inc.
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
6
States / cities
Miami, Florida • Boston, Massachusetts • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2025 · Synced Sep 15, 2026, 8:45 PM EDT
Completed Phase 4 Interventional

The Comparison of Supraperiosteal Nerve Block With Opiate Analgesia in Alleviating the Pain of Toothache

NCT00574015
View directory record Official record
Conditions
Toothache
Interventions
hydrocodone/acetaminophen, bupivacaine (supraperiosteal nerve block)
Drug
Lead sponsor
Albany Medical College
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Albany, New York
Source: ClinicalTrials.gov public record
Updated Mar 23, 2014 · Synced Sep 15, 2026, 8:45 PM EDT
Terminated Phase 2 Interventional Results available

Genetic Predictors of Benefit to Pembrolizumab

NCT02710396
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pembrolizumab, Carboplatin, Nab-paclitaxel, Pemetrexed
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
New York, New York • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2023 · Synced Sep 15, 2026, 8:45 PM EDT
Completed Phase 2 Interventional Results available

Perioperative Chemo and Pembrolizumab in Gastric Cancer

NCT02918162
View directory record Official record
Conditions
Gastric Cancer, Adenocarcinoma of the Gastroesophageal Junction
Interventions
Pembrolizumab, Standard of care chemotherapy regimen
Drug
Lead sponsor
Gulam Manji
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
4
States / cities
St Louis, Missouri • New York, New York • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Sep 15, 2026, 8:45 PM EDT
Completed Not applicable Interventional Results available

Acupuncture for Low-Dose Opioid for TKA Replacement

NCT04084288
View directory record Official record
Conditions
Knee Osteoarthritis, Pain, Postoperative, Acupuncture
Interventions
Acupuncture, Peripheral Nerve Stimulator
Other · Device
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 70 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 26, 2024 · Synced Sep 15, 2026, 8:45 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer

NCT07335796
View directory record Official record
Conditions
Prostate Cancer
Interventions
BMS-986165, Degarelix
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
6
States / cities
Basking Ridge, New Jersey • Montvale, New Jersey • Commack, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 15, 2026, 8:45 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of EXPAREL, EXPAREL Admixed With Bupivacaine HCl vs. Bupivacaine HCl Administered as Combined Sciatic and Saphenous Nerve Blocks for Postsurgical Analgesia in Subjects Undergoing Lower Extremity Surgeries

NCT04518462
View directory record Official record
Conditions
Lower Extremity Surgery, Bunion, Metatarsophalangeal Fushion, Midfoot Fusion, Hindfoot Fushion, Total Ankle Arthroplasty
Interventions
Exparel, Bupivacaine Hydrochloride
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Phoenix, Arizona • Pasadena, California • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2022 · Synced Sep 15, 2026, 8:45 PM EDT
Completed Phase 2 Interventional Results available

Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. Nivolumab

NCT04401995
View directory record Official record
Conditions
Melanoma
Interventions
Vidutolimod (CMP-001), Nivolumab, [18F]F-AraG PET/CT
Drug · Biological · Other
Lead sponsor
Diwakar Davar
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Sep 15, 2026, 8:45 PM EDT
Completed Phase 4 Interventional Results available

A 16-Week Study to Evaluate the Effect of Advair DISKUS™ 250/50mcg on Arterial Stiffness in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT00857766
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
ADVAIR DISKUS™ 250/50mcg, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
24
States / cities
Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 15, 2026, 8:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics Study of ALO-02 and OxyContin

NCT01557257
View directory record Official record
Conditions
Management of Moderate to Severe Pain
Interventions
ALO-02, Naltrexone block, OxyContin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 27, 2012 · Synced Sep 15, 2026, 8:45 PM EDT
Recruiting Not applicable Interventional

Medical Management With Endovascular Thrombectomy Versus Medical Management Alone in Patients Presenting Beyond 24 Hours of Last Known Well

NCT07115940
View directory record Official record
Conditions
Acute Ischemic Stroke
Interventions
Endovascular Thrombectomy, Medical Management
Device · Other
Lead sponsor
Amrou Sarraj
Other
Eligibility
18 Years to 85 Years
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
6
States / cities
Chicago, Illinois • Kansas City, Kansas • St Louis, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2026 · Synced Sep 15, 2026, 8:45 PM EDT